Sperm Freezing: Why It Has to Happen Before Treatment

Before cancer-directed treatment starts, if that is what you are facing. ASCO's 2025 guideline update recommends that sperm cryopreservation be offered to males before treatment begins, and that testicular sperm extraction be used where a semen sample cannot be produced. It also asks that men be counselled about reproductive risk at diagnosis rather than later.

The reason the timing is not negotiable is in the guideline itself: it advises that men be told of a potentially higher risk of genetic damage in sperm collected soon after cancer-directed therapy has started, and soon after it has finished. So the window is before, not during, and not immediately afterwards.

Being asked to produce a sample in a hospital days after a cancer diagnosis is a genuinely hard thing to be asked, and it is the one part of this that cannot be moved later without cost. Everything else on this page can wait until after the first sample is in the bank.

Oncofertility is where the evidence for banking is strongest. Other reasons exist — before a vasectomy, before gender-affirming hormone therapy, or to have a sample available on the day of a treatment cycle — but they are not what the guideline evidence was built on. The wider picture for men treated for cancer is in male fertility after cancer treatment and fertility preservation for cancer patients.

There are pooled figures, and they only mean anything with their denominators attached. A systematic review and meta-analysis brought together 69 non-randomised studies: 32,234 men were referred for sperm analysis and 23,178 banked at least one sample. Among those who went on to use their samples, clinical pregnancy per cycle was:

• ICSI — 34% per cycle (95% confidence interval 27-41), with a delivery rate of 23% per cycle (17-30)
• IVF — 24% per cycle (14-35), with a delivery rate of 18% per cycle (11-26)
• IUI — 9% per cycle (5-15), with a delivery rate of 5% per cycle (1-9)

Two things follow. The first is that the technique matters more than anything about the freezing: ICSI injects a single sperm into an egg, which is why it tolerates a thawed sample with few motile sperm. The second is that these are rates per cycle, not per patient, and a couple who go through several cycles are not facing the per-cycle figure each time in isolation.

The analysis is honest about its own limits, and they are worth carrying forward. The studies span 36 years, over which the WHO semen standards were revised more than once. It does not relate cancer type to sperm quality. Many of the earlier studies were small and had no control group, and almost none accounted for how advanced the disease was.

Most of it is never used, and that is the figure nobody puts in the brochure. In the same pooled analysis, the sperm use rate was 9% (95% confidence interval 8-10) and the disposal rate 23% (16-30). Nine in ten men who bank do not draw on the samples.

That is not an argument against banking, and it is worth being clear why. Many men recover sperm production after treatment and conceive without help. Some never need to try. The decision is being made at a point when nobody can tell which group you are in, and the cost of being wrong is asymmetric — a sample not taken cannot be taken later from a testis that has stopped producing.

One more figure from that analysis is worth knowing before the appointment: the pooled failed-to-cryopreserve rate was 10% (95% confidence interval 8-12). Roughly one man in ten who is referred does not end up with a usable banked sample, whether because no sample could be produced or because there was nothing viable in it. That is the situation the guideline's testicular sperm extraction recommendation exists for, and it is a reason to start the conversation early rather than on the day.

On the best available comparison, no. A German centre examined samples from its archive of 6,022 patients frozen between 2001 and 2019, using the 293 samples donated for research once storage was ended, and grouped them by how long they had been stored — 2.5 to 5 years, 5 to 14 years, and more than 14 years.

Across those groups there was no difference in motility (p = 0.44), vitality (p = 0.08) or morphology (p = 0.44). On regression, what predicted post-storage motility was the motility and sperm concentration of the sample when it went in; storage duration did not (p = 0.72), and neither did it predict vitality (p = 0.64). The same held for men whose semen parameters were poor to begin with, which is the group this question usually gets asked about.

A case report describes two live births from intrauterine insemination using semen from one man, banked before cancer treatment and stored for 21 and 28 years. That is a case report of one man and two births, not a rate — but it is the longest documented interval, and it is consistent with the archive study.

What this does mean is that the sample's quality on the day it is frozen is what you are storing, so how that sample was produced matters. Our guides to preparing for a semen analysis and reading a semen analysis report cover the collection and the numbers.

Two provisions of the ART (Regulation) Act, 2021 bear on this, and the second is more often misquoted than read.

• Section 27(1) — the collection, screening and storage of semen may be done only by a bank registered as an independent entity under the Act. A clinic that is not a registered bank is not the place for this.
• Section 28(1) — the standards for storage and handling of gametes, gonadal tissues and embryos, covering security, recording and identification, are left to be prescribed by rules rather than set in the Act.
• Section 28(2) — "The gamete of a donor or embryo shall be stored for a period of not more than ten years", after which it is allowed to perish or is donated to a registered research organisation with the consent of the commissioning couple or individual.

Read section 28(2) carefully, because the ten-year cap is written for the gamete of a donor, and for embryos. By its terms it does not address a man's own sperm banked for his own later use, and this page does not claim it does either way. What follows practically is that the duration applying to your samples is a question for your bank, in writing, along with the annual fee, what happens if a payment is missed, and what happens to the samples on death.

Cost is the part this page cannot source. No price for sperm banking or annual storage in India was found in retrievable published literature, so there is no figure here. For scale rather than for a quote: across five tertiary Indian facilities, the annual median out-of-pocket expenditure for male-infertility care was ₹13,211 (IQR ₹6,654 to ₹21,521), and catastrophic health expenditure affected 59.4% of the participants. That measures infertility care in general, not banking, and should not be read as a price for freezing.

This is a field written about more confidently than the data allows, and the gaps run in a particular direction — towards making banking sound more like a solution and less like insurance.

• That freezing protects against age-related decline. Nothing retrieved here tested banking in healthy men to offset paternal age. The storage evidence shows a sample keeps the quality it had when frozen; it says nothing about whether banking at 30 improves anything at 45. Sperm freezing is not the male equivalent of elective egg freezing, and the marketing that presents it that way is ahead of the evidence.
• That frozen performs as well as fresh. No head-to-head comparison was retrieved. What exists is per-cycle rates from frozen samples, which cannot answer the question on their own.
• How many samples to bank. Not addressed in anything retrieved. The constraint named in the guideline is the time available before treatment starts, not a target number.
• A price for banking or storage in India. Searched and not found in published literature.
• Whether the ten-year cap in section 28(2) reaches a man's own samples. The provision is written for donor gametes and embryos, and the storage standards are left to rules under section 28(1).

Two caveats about the sources themselves. The ASCO 2025 guideline carries two published errata, and their content was not retrieved for this page, so only recommendation language has been quoted from it. And the post-thaw storage evidence comes from one centre's archive, using 293 samples donated out of 6,022 patients' holdings, which is a selected subset rather than a random sample of what is in storage.

One thing the guideline is unambiguous about: freezing testicular tissue in boys who have not started puberty is experimental, and ASCO 2025 says it should be offered only within a clinical trial. If it is offered to you outside one, that is worth questioning.